CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DEGFRS768IPredictiveDoes Not SupportSensitivity/ResponseCancerErlotinib,GefitinibKancha et al., 2009
DEGFRR831HPredictiveSupportsSensitivity/ResponseCancerErlotinibFoster et al., 2010
DEGFRL858RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinibYasuda et al., 2013
CEGFRL858RPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibDoebele et al., 2012
DEGFRL858RPredictiveDoes Not SupportSensitivity/ResponseLung AdenocarcinomaCetuximabKonduri et al., 2016
DEGFRL858RPredictiveSupportsSensitivity/ResponseHigh Grade GliomaErlotinibLee et al., 2006
BEGFRL861PredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib,GefitinibWu et al., 2011
DEGFRL861QPredictiveSupportsSensitivity/ResponseHigh Grade GliomaErlotinibLee et al., 2006
DEGFRE868GPredictiveSupportsSensitivity/ResponseCancerErlotinibFoster et al., 2010
BBCR::ABL1Fusion AND ABL1 M244VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
BBCR::ABL1Fusion AND ABL1 G250EPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
CBCR::ABL1Fusion AND ABL1 Q252HPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
CBCR::ABL1Fusion AND ABL1 Y253HPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
BBCR::ABL1Fusion AND ABL1 Y253HPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
BBCR::ABL1Fusion AND ABL1 E255KPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
CBCR::ABL1Fusion AND ABL1 E255KPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 D276GPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
BBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
CBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 F317LPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 M351TPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 E355GPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 L387MPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
CBCR::ABL1Fusion AND ABL1 L387MPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
BBCR::ABL1Fusion AND ABL1 H396RPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
CPIK3CAE542KPredictiveDoes Not SupportResistanceColorectal CancerCetuximabDe Roock et al., 2010
BKRASG12APredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
CPIK3CAH1047LPredictiveSupportsResistanceColorectal CancerIrinotecan,CetuximabDe Roock et al., 2010
CBCR::ABL1Fusion AND ABL1 L364IPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1FusionPredictiveSupportsSensitivity/ResponseAcute Lymphoblastic LeukemiaDasatinibTalpaz et al., 2006
BBCR::ABL1Fusion AND ABL1 E255VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
CBCR::ABL1Fusion AND ABL1 E255VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
DKITP551_E554delPMYEPredictiveDoes Not SupportSensitivity/ResponseGastrointestinal Stromal TumorImatinib,Regorafenib Anhydrous,SunitinibGarner et al., 2014
CPIK3CAS158LPredictiveSupportsResistanceColorectal CancerIrinotecan,CetuximabDe Roock et al., 2010
CBRAFD594GPredictiveSupportsResistanceColorectal CancerCetuximab,IrinotecanHsu et al., 2016
CBCR::ABL1Fusion AND ABL1 F359CPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
DARID1AQ456*PredictiveSupportsSensitivity/ResponseColorectal CancerDasatinibMiller et al., 2016
DBRAFV600DPredictiveSupportsSensitivity/ResponseMelanomaVemurafenibTsai et al., 2008
CEGFRH773_V774insNPHPredictiveSupportsResistanceLung AdenocarcinomaErlotinibYasuda et al., 2013
DEGFRVIIIPredictiveSupportsSensitivity/ResponseHigh Grade GliomaErlotinibLee et al., 2006
DERBB2L755SPredictiveSupportsResistanceCecum AdenocarcinomaCetuximabKavuri et al., 2015
DAKT3E17KPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
BBCR::ABL1Fusion AND ABL1 F359IPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
CBCR::ABL1Fusion AND ABL1 F359IPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 V299LPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibSoverini et al., 2016
CBCR::ABL1Fusion AND ABL1 E279KPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
BBCR::ABL1Fusion AND ABL1 F486SPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
DKITK558delinsNPPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorSunitinib,Ponatinib,Imatinib,Regorafenib AnhydrousGarner et al., 2014
CPDGFRAD842VPredictiveSupportsResistanceGastrointestinal Stromal TumorSunitinibHeinrich et al., 2008
DKITA502_Y503dupPredictiveDoes Not SupportSensitivity/ResponseCancerPonatinib,Regorafenib Anhydrous,ImatinibGarner et al., 2014
Page 44 of 96
PreviousNext